Eight-patient Parkinson's stem cell clinical trial confirms feasibility

AI Summary

A pioneering clinical trial led by researchers in Lund, Sweden demonstrated that transplanting stem cell-derived dopamine progenitors into Parkinson's patients' brains is feasible and safe. Eight patients participated with no serious side effects reported during a year-long follow-up, as published in Nature Medicine.

A landmark study led by Lund, Sweden, has shown that transplanting stem cell-derived dopamine progenitor cells into the brain is feasible. Eight patients were transplanted in the first clinical trial, and no serious side effects linked to the transplanted cells were seen during the first year of follow-up. The results are published in Nature Medicine.